- Medpace (MEDP, Financial) shares tumble despite surpassing financial forecasts.
- Revenue up 9% year-over-year, but new net business awards decline.
- Analysts provide a "Hold" rating with significant potential upside.
Shares of Medpace (MEDP) experienced a downturn as the company's Q1 2025 financial results exceeded expectations; however, key performance indicators didn't meet analysts' standards. Revenue saw an increase of 9% year-over-year, reaching $558.6 million. Despite this growth, the new net business awards took a hit, dropping 19% to $500 million. Additionally, the critical book-to-bill ratio came in at 0.9x, falling short of market anticipations.
Wall Street Analysts' Predictions
Wall Street analysts have offered a range of price targets for Medpace Holdings Inc (MEDP, Financial) over the next year. The consensus average target price is $330.33, with estimates ranging from a high of $404.00 to a low of $280.00. This average projection suggests a potential upside of 19.51% from the current stock price of $276.41. For more in-depth estimate data, visit the Medpace Holdings Inc (MEDP) Forecast page.
The consensus recommendation from 11 brokerage firms places Medpace Holdings Inc's (MEDP, Financial) average brokerage recommendation at 2.6, indicating a "Hold" status. On the rating scale, 1 denotes a Strong Buy, while 5 suggests a Sell.
According to GuruFocus estimates, the projected GF Value for Medpace Holdings Inc (MEDP, Financial) in one year is $365.69. This indicates a potential upside of 32.3% from the current price of $276.405. The GF Value reflects GuruFocus' assessment of the fair market value for the stock, calculated using historical trading multiples, past business growth, and future performance estimates. For more comprehensive data, refer to the Medpace Holdings Inc (MEDP) Summary page.
